Levonorgestrel
and Ethinyl Estradiol (Levelen) |
Category:
Description:
Indications:
Contraindications:
-
Pregnancy
and lactation
-
Undiagnosed
abnormal vaginal bleeding
-
Known
or suspected benign or malignant liver tumors while on oral
contraceptive use
- Breast carcinoma or estrogen-dependent neoplasia
-
Current
or history of thromboembolic disorders, cerebral vascular or
cardiovascular disease.
Precautions:
-
Pregnancy
category X
-
Take
as directed at intervals not exceeding 24 hours. Efficiency is dependent upon strict compliance.
-
Breakthrough
bleeding (“spotting”) may occur during initiation of therapy.
-
Instructions
for missed doses:
-
One
missed dose: Take as soon as possible or two tablets the next day
and continue
-
Two
missed doses: Take two tablets daily for two days, then continue
normal schedule
-
Three
missed doses: Discontinue therapy and begin new packet 7 days
following last dose
-
May
cause mental depression, fluid retention and depressed folate levels
-
Twenty-eight
day packs contain seven days of inert ingredients to maintain regimen
-
Begin
therapy on the fifth day of the cycle. Day one of cycle is the first day of menstrual bleeding.
Adverse
Reactions (Side Effects):
-
Abdominal
cramping, anorexia, nausea, vomiting
-
Acne
-
Edema,
weight gain
-
Unusual
tiredness or weakness
-
Cardiovascular
disorders (hypertension)
-
Thromboembolic
disorders
|
Dosage:
Administered
orally
For
more information on Oral Contraceptive Pills, read:
|
|
|
|
The information contained here is an
abbreviated summary. For more detailed and complete information, consult the
manufacturer's product information sheets or standard textbooks
Source: Operational Medicine 2001, Health
Care in Military Settings, NAVMED P-5139, May 1, 2001, Bureau
of Medicine and Surgery, Department of the Navy, 2300 E Street NW, Washington,
D.C., 20372-5300
This information is provided by The Brookside Associates. The Brookside
Associates, LLC. is a private organization, not affiliated with any governmental
agency. The opinions presented here are those of the author and do not
necessarily represent the opinions of the Brookside Associates or the Department
of Defense. The presence of any advertising on these pages does not constitute
an endorsement of that product or service by either the US Department of Defense
or the Brookside Associates. All material presented here is unclassified.
C. 2009, 2014, All Rights Reserved
|
|